P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH ZANUBRUTINIB VS IBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (RR) CLL/SLL: RESULTS FROM THE RANDOMIZED PHASE 3 ALPINE TRIAL

Hillmen, P., Brown, J., Lamanna, N., O’Brien, S., Tam, C., Qiu, L., Yang, K., Barnes, G., Wu, K., Salmi, T., & Eichhorst, B. (2022). P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH ZANUBRUTINIB VS IBRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (RR) CLL/SLL: RESULTS FROM THE RANDOMIZED PHASE 3 ALPINE TRIAL. HemaSphere, 6, 561–562. https://doi.org/10.1097/01.hs9.0000845536.66920.d3

Authors:

Peter Hillmen

J. Brown

Nicole Lamanna

Sarah H. O’Brien

Constantine S. Tam

L. Qiu

K. Yang

G. Barnes

K. Wu

T. Salmi

B. Eichhorst